Can a rapid lab test guide treatment for rare gynecologic cancers?

NCT ID NCT07731880

First seen Jul 28, 2026 · Last updated Aug 07, 2026 · Updated 3 times

Summary

This study explores whether a tool called SmartMatch can quickly analyze tumor tissue from standard surgeries or biopsies to suggest personalized treatment options for people with rare, advanced gynecologic cancers. The goal is to see how often SmartMatch can produce a useful treatment recommendation within four weeks. If it works, this approach could speed up access to tailored therapies for hard-to-treat cancers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SmartMatch functional precision medicine analysis
What this could lead to
If successful, this approach could help match patients with rare gynecologic cancers to effective treatments faster, potentially improving outcomes.
What could go wrong
This is a small feasibility study with only 30 participants, so results may not apply broadly. The analysis may not always yield actionable recommendations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MALIGNANT FEMALE REPRODUCTIVE SYSTEM NEOPLASM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Fred Hutch/University of Washington Cancer Consortium

    RECRUITING

    Seattle, Washington, 98109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.